| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $50.5M | +18.0% | +58.3% |
| SG&A Expense | $11.9M | -6.9% | -19.5% |
| Operating Income | -$62.4M | -12.3% | -33.7% |
| Net Income | -$61.5M | -13.2% | -39.8% |
| EPS (Basic) | -$1.16 | -12.6% | -38.1% |
| EPS (Diluted) | -$1.16 | -12.6% | -38.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $72.0M | -30.8% | -63.6% |
| Current Assets | $75.7M | -29.8% | -62.6% |
| Total Assets | $218.1M | -15.1% | -41.5% |
| Current Liabilities | $42.4M | +36.8% | +76.3% |
| Total Liabilities | $194.4M | +4.3% | +3.8% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$96.6M | — | — |
| Capital Expenditures | $463K | — | — |
| Investing Cash Flow | -$463K | — | — |
| Financing Cash Flow | $1.1M | — | — |
| Free Cash Flow | -$97.1M | — | — |
| $23.7M |
| -66.3% |
| -87.2% |